Work

Supplementary Figures S1 and S2 from Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes PTEN/TP53-Deficient Prostate Cancer to Radiation

Year: 2023

Type: supplementary-materials

Abstract: Figure S1. Drug dose-dependent enhancement of γ-H2AX and Rad51 expression using NanoOlaparib; Figure S2. Representative confocal microscopy images of Rad51 and Polθ immunostaining 30 minutes following irradiation.

DOI: 10.1158/1535-7163.22509091

Authors: Anne L. van de Ven, Shifalika Tangutoori, Paige Baldwin, Ju Qiao, Codi Gharagouzloo, Nina Seitzer, John G. Clohessy, G. Mike Makrigiorgos, Robert Cormack, Pier Paolo Pandolfi, Srinivas Sridhar

Institutions: Northeastern University, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362485217

Cites:

Cited by:

Related to: 10